Clinical Trial Update: LDFWART With Docetaxel in Patients With Platinum-Resistant Recurrent Ovarian Carcinoma [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating LDFWART in combination with docetaxel for platinum-resistant recurrent ovarian cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• LDFWART

Snippet

Sponsor: University of Miami | Conditions: Ovarian Cancer, Ovarian Carcinoma | Phase 1 | Status: WITHDRAWN